Skip to main content
    E

    Enliven Therapeutics Inc. (ELVN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $47.62
    -1.18 (-2.42%)

    Market Cap: $3.59B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Enliven Therapeutics Inc. (ELVN) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Enliven Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$103.69M, operating cash flow was -$70.30M and free cash flow was -$70.46M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$27.70M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $119.66M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018N/AN/AN/AN/AN/A
    Dec 2017N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Research and development$85.86M$80.78M$64.57M$31.02M$38.44M$32.15M$19.01M$8.24M$7.92M
    Operating income-$119.66M-$104.55M-$83.53M-$38.79M-$51.44M-$41.70M-$24.12M-$10.68M-$8.90M
    Net income-$103.69M-$89.02M-$71.58M-$37.66M-$51.38M-$41.36M-$23.46M-$11.34MN/A
    EBITDAN/A-$103.81MN/A-$38.58M-$51.36M-$41.62M-$24.03MN/A$221.00K
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$316.00K$0$0$0$440.00K
    Gross profit$0$0$0-$46.00K$0$0$0$158.00K$0$0$0$363.00K
    Operating income-$36.05M-$37.21M-$27.82M-$34.28M-$25.10M-$28.58M-$31.69M-$26.90M-$27.07M-$24.60M-$25.99M-$22.73M
    Net income-$27.70M-$32.48M-$23.63M-$29.67M-$20.15M-$25.34M-$28.54M-$23.18M-$23.16M-$19.95M-$22.74M-$19.37M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $399.00K by $98.50M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$476.17M$325.76M$271.87M$83.30M$93.65M$90.84M$33.30M$7.71M$10.22M
    Current assets$474.88M$318.13M$266.15M$77.75M$92.70M$90.41M$30.62M$7.71M$10.22M
    Cash and equivalents$98.90M$124.12M$100.14M$75.54M$48.31M$47.70M$4.94M$7.38M$9.67M
    Total liabilities$16.57M$15.91M$25.96M$10.37M$7.62M$6.41M$4.38M$1.83M$1.49M
    Short-term debt$399.00KN/A$335.00K$323.00K$159.00K$105.00KN/AN/AN/A
    Shareholder equity$459.60M$309.85M$245.91M-$76.83M$86.03M$84.44M-$48.85M-$26.32M-$15.53M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$897.23M$910.22M$464.85M$476.17M$490.88M$503.89M$302.57M$325.76M$305.43M$327.04M$342.78M$271.87M
    Total liabilities$20.28M$15.07M$11.49M$16.68M$14.75M$15.41M$14.27M$15.91M$17.03M$22.11M$25.07M$25.96M
    Cash and equivalents$151.67M$135.50M$132.18M$98.90M$101.73M$119.44M$101.70M$124.12M$100.62M$96.87M$149.16M$100.14M
    Shareholder equity$876.95M$895.15M$453.37M$459.60M$476.12M$488.47M$288.30M$309.85M$288.40M$304.93M$317.71M$245.91M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$70.30M-$73.19M-$61.27M-$32.08M-$46.77M-$37.40M-$21.88M-$8.78M-$8.79M
    Capital expenditures$158.00K$44.00K$149.00K$612.00K$12.00K$18.00K$140.00K$0$0
    Free cash flow-$70.46M-$73.24M-$61.42M-$32.69M-$46.78M-$37.42M-$22.02M-$8.78M-$8.79M
    Dividends paidN/AN/A$8.74M$0N/AN/AN/AN/AN/A
    Share repurchasesN/AN/AN/AN/A$578.00K$1.72M$2.00MN/AN/A
    Investing cash flow-$173.84M-$36.00M-$148.41M-$612.00K-$1.63M-$16.72M-$24.06MN/AN/A
    Financing cash flow$218.87M$133.16M$234.29M-$1.80M$49.10M$96.88M$43.58M$6.49M$11.00M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$12.55M-$18.53M-$19.29M-$15.84M-$13.28M-$17.06M-$24.13M-$17.20M-$12.19M-$20.43M-$23.36M-$12.48M
    Capital expenditures$94.00K$99.00K$0$0$1.00K$139.00K$20.00K$0$22.00K$2.00K$20.00K$14.00K
    Free cash flow-$12.65M-$18.63M-$19.29M-$15.84M-$13.28M-$17.20M-$24.15M-$17.20M-$12.21M-$20.44M-$23.38M-$12.50M
    Last 12 quarters

    Frequently Asked Questions About ELVN

    What is Enliven Therapeutics' annual revenue?

    Enliven Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Enliven Therapeutics profitable?

    No. Enliven Therapeutics reported net income of -$103.69M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does ELVN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$70.30M minus capital expenditures of $158.00K produced free cash flow of -$70.46M.

    How much debt does Enliven Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $399.00K and cash and equivalents of $98.90M.